Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
November 6, 2025 7:00 AM ESTAxsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA 2,3 receptor positive allosteric modulator
Deepens Axsomes broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into an agreement to obtain exclusive global rights to AZD7325, a novel oral GABAA receptor 2,3 subtype-selective... More
